Inhibition of Vasoconstriction by Amlodipine in Human Internal Mammary Arteries Used as Bypass Grafts

Guo-Wei He,Xiao-Yan Bai,Xiao-Cheng Liu,Wen-Bin Jing,Li Fan,Qin Yang
DOI: https://doi.org/10.1096/fasebj.24.1_supplement.573.1
2010-01-01
Abstract:Graft spasm remains challenging in coronary artery bypass grafting (CABG). We studied the inhibitory effect of a dihydropyridine calcium antagonist amlodipine in 70 human internal mammary artery (IMA) segments from 34 patients undergoing CABG in organ baths in two ways: the relaxing effect of amlodipine on vasoconstrictor‐induced precontraction by potassium chloride (KCl), human urotensin II (hU‐II), and U46619 and the depressing effect of amlodipine on the contraction. Amlodipine caused full relaxation in KCl (98.0±2.1%)‐ and hU‐II (98.5±2.4%)‐ but not in U46619‐contracted IMA rings (n=8) with 15.5‐fold higher potency to KCl than to hU‐II (EC50: −8.17±0.28 vs. −6.98±0.01 logM, p<0.001). Pretreatment of IMA with plasma‐concentrations of amlodipine (−7.6 and −6.6 logM, n=6) significantly depressed subsequent contraction to KCl (from 20.8±2.5 to 16.6±2.6 mN and from 20.8±2.5 to 7.6±3.0 mN, p<0.05) and hU‐II (from 14.1±4.2 to 11.4±3.7 mN and from 14.1±4.2 to 3.8±2.0 mN, p<0.05) but not to U46619. Thus, in human IMA, amlodipine has a selective inhibitory effect on the vasoconstriction mediated by vasoconstrictors with high potency on KCl and hU‐II and amlodipine may be effectively used in CABG patients for treatment and prevention of graft spasm. Supported by Tianjin Municipal Sci & Tech Com (09ZCZDSF04200); Ministry of Sci & Tech, China (2009DFB30560); Providence SVMF, OR & Hong Kong GRF 465107, 478909.
What problem does this paper attempt to address?